4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
8.28 (USD) • At close November 7, 2024
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Omzet
| 20.723 | 3.129 | 18.038 | 13.612 | 6.986 | 14.13 | 5.79 |
| Kosten van de omzet
| 5.749 | 3.88 | 3.02 | 53.038 | 38.718 | 18.362 | 13.573 |
| Brutowinst
| 14.974 | -0.751 | 15.018 | -39.426 | -31.732 | -4.232 | -7.783 |
| Brutowinstmarge
| 0.723 | -0.24 | 0.833 | -2.896 | -4.542 | -0.3 | -1.344 |
| Onderzoek- en ontwikkelingskosten
| 97.096 | 80.253 | 61.36 | 53.038 | 38.718 | 18.362 | 13.573 |
| Algemene en administratieve kosten
| 36.494 | 32.908 | 28.011 | 17.238 | 13.895 | 6.167 | 3.489 |
| Verkoop- en marketingkosten
| -5.749 | 0 | 0 | 0 | 0 | 0 | 0 |
| Verkoop-, algemene en administratieve kosten
| 30.745 | 32.908 | 28.011 | 17.238 | 13.895 | 6.167 | 3.489 |
| Overige kosten
| -0.181 | 2.538 | 0.016 | -0.181 | -0.046 | -0.002 | -0.04 |
| Bedrijfskosten
| 127.841 | 113.161 | 89.371 | 70.276 | 52.613 | 24.529 | 17.062 |
| Bedrijfsresultaat
| -112.867 | -110.032 | -71.333 | -56.664 | -50.764 | -10.399 | -11.272 |
| Bedrijfsresultaat ratio
| -5.446 | -35.165 | -3.955 | -4.163 | -7.267 | -0.736 | -1.947 |
| Totaal overige inkomsten en kosten netto
| 12.03 | 2.538 | 0.016 | -0.029 | 1.458 | -0.002 | -0.04 |
| Inkomen voor belasting
| -100.837 | -107.494 | -71.317 | -56.693 | -49.306 | -9.551 | -11.223 |
| Inkomen voor belasting ratio
| -4.866 | -34.354 | -3.954 | -4.165 | -7.058 | -0.676 | -1.938 |
| Belastingkosten
| 5.581 | -6.418 | -3.02 | -0.152 | 3.633 | 0.848 | -0.089 |
| Nettowinst
| -100.837 | -101.076 | -68.297 | -56.541 | -52.939 | -9.551 | -11.223 |
| Nettowinstmarge
| -4.866 | -32.303 | -3.786 | -4.154 | -7.578 | -0.676 | -1.938 |
| WPA (Winst Per Aandeel)
| -2.58 | -3.12 | -2.46 | -2.12 | -2 | -0.76 | -0.76 |
| Verwaterde WPA
| -2.58 | -3.12 | -2.46 | -2.12 | -2 | -0.76 | -0.76 |
| EBITDA
| -107.118 | -110.032 | -71.333 | -55.221 | -39.486 | -9.702 | -10.646 |
| EBITDA ratio
| -5.169 | -35.165 | -3.955 | -4.057 | -5.652 | -0.687 | -1.839 |